[Federal Register Volume 63, Number 39 (Friday, February 27, 1998)] [Notices] [Page 10028] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-5049] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Allergenic Products Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public. Name of Committee: Allergenic Products Advisory Committee. General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues. Date and Time: The meeting will be held on March 24, 1998, 1 p.m. to 4:30 p.m. by teleconference. Location: Food and Drug Administration, Bldg. 29, conference room 121, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by telephone conference call. A speaker phone will be provided in the conference room to allow public participation in the meeting. Contact Person: William Freas or Sheila D. Langford, Center for Biologics Evaluation and Research (HFM-21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314 or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443- 0572 in the Washington, DC area), code 12388. Please call the Information Line for up-to-date information on this meeting. Agenda: The committee will receive an update on the status of standardized grasses and discuss how candidate allergens for future standardization should be identified. Procedure: On March 24, 1998, from 1 p.m. to 3 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 18, 1998. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal presentations should notify the contact person before March 18, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Closed Committee Deliberations: On March 24, 1998, from 3 p.m. to 4 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). This portion of the meeting will be closed to hear and review trade secret and/or confidential information on pending investigational new drugs. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: February 20, 1998. Michael A. Friedman, Deputy Commissioner for Operations. [FR Doc. 98-5049 Filed 2-26-98; 8:45 am] BILLING CODE 4160-01-F